Vetter invests almost 500 million euros in new production site
Groundbreaking ceremony marks the start of the first construction phase
Advertisement
Vetter celebrates the start of construction work for the new site in Saarlouis with a traditional ground-breaking ceremony. In the first construction phase, a modern production facility for the commercial manufacture of injectable drugs is being built on the approximately 40-hectare industrial site. In total, Vetter will invest almost half a billion euros at the site by the time it is scheduled to go into operation in 2031. This underlines the company's strong position as one of the technology leaders with the highest quality standards. Initially, 400 to 500 new jobs are planned. By the final expansion stage of the first construction phase, the pharmaceutical service provider expects to create up to 1,500 jobs. In the future, up to 2,000 jobs are possible.
The first expansion phase includes the construction of a 50,000m2 production building and other production-related facilities such as laboratories and warehouses. Initially, three state-of-the-art cleanrooms are planned for the aseptic production of innovative and complex medicines - two cleanrooms for filling pre-sterilized syringes and one cleanroom for filling vials.
Comments on the ground-breaking ceremony
Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family: "Today's ground-breaking ceremony marks a decisive step for the future of our family business. With the new site in Saarlouis, we are setting the course for further sustainable growth. We are creating the conditions to further expand our capacities in the production of complex medicines and to continue to offer our international customers the resources, quality and reliability that they need and have come to expect from us. At the same time, we are sustainably strengthening Germany as an industrial location."
Anke Rehlinger, Minister President of Saarland: "Today is a good day for Saarland: with Vetter, a strong, innovative company is joining us - and with it, new opportunities for many people. Here in Saarlouis, we can see that structural change succeeds when we actively shape it."
Jürgen Barke, Saarland Minister of Economic Affairs: "A high-tech settlement like this makes us one of the most sought-after locations for the pharmaceutical industry and shows how transformation can succeed: new, sustainable jobs and a strong industry of the future. This will trigger knock-on effects the likes of which we have never seen before."
Patrik Lauer, District Administrator of the Saarlouis district: "Together with Vetter as an anchor, we want to usher in a new economic era in our region and write another success story. We are looking forward to a strong company that will attract other companies from nearby sectors with its innovative strength. We are ready for this with a well-trained and motivated workforce, an outstanding educational offer and an excellent infrastructure."
Marc Speicher, Lord Mayor of Saarlouis: "The establishment of Vetter strengthens Saarlouis and Saarland as a business location. As a successful, international family business, Vetter fits in perfectly with our Saarlouis economic and settlement strategy. Vetter is not only investing here in Saarlouis, but we are also entering into a long-term community and development partnership: For a strong economy and good jobs. We have worked on the settlement in the town hall at record speed and I am looking forward to the years together with Vetter in Saarlouis."
Global investment in the future
For over 75 years, Vetter has stood for quality, innovation and responsibility to improve the quality of life of patients worldwide. In order to meet the growing demand and increasing market requirements, the company is investing sustainably in its pharmaceutical production sites in Germany, Austria and the USA. With the new site in Saarlouis, Vetter is once again significantly expanding its production capacities.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
